Cargando…
A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid
Bone morphogenic proteins (BMPs) are the only true osteoinductive molecules. Despite being tremendously potent, their clinical use has been limited for reasons including supraphysiological doses, suboptimal delivery systems, and the pro-osteoclast effect of BMPs. Efforts to achieve spatially control...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695465/ https://www.ncbi.nlm.nih.gov/pubmed/33246951 http://dx.doi.org/10.1126/sciadv.abc1779 |
_version_ | 1783615195090780160 |
---|---|
author | Raina, Deepak Bushan Matuszewski, Lucas-Maximilian Vater, Corina Bolte, Julia Isaksson, Hanna Lidgren, Lars Tägil, Magnus Zwingenberger, Stefan |
author_facet | Raina, Deepak Bushan Matuszewski, Lucas-Maximilian Vater, Corina Bolte, Julia Isaksson, Hanna Lidgren, Lars Tägil, Magnus Zwingenberger, Stefan |
author_sort | Raina, Deepak Bushan |
collection | PubMed |
description | Bone morphogenic proteins (BMPs) are the only true osteoinductive molecules. Despite being tremendously potent, their clinical use has been limited for reasons including supraphysiological doses, suboptimal delivery systems, and the pro-osteoclast effect of BMPs. Efforts to achieve spatially controlled bone formation using BMPs are being made. We demonstrate that a carrier consisting of a powder of calcium sulfate/hydroxyapatite (CaS/HA) mixed with bone active molecules provides an efficient drug delivery platform for critical femoral defect healing in rats. The bone-active molecules were composed of osteoinductive rhBMP-2 and the bisphosphonate, and zoledronic acid (ZA) was chosen to overcome BMP-2–induced bone resorption. It was demonstrated that delivery of rhBMP-2 was necessary for critical defect healing and restoration of mechanical properties, but codelivery of BMP-2 and ZA led to denser and stronger fracture calluses. Together, the CaS/HA biomaterial with rhBMP-2 and/or ZA can potentially be used as an off-the-shelf alternative to autograft bone. |
format | Online Article Text |
id | pubmed-7695465 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76954652020-12-04 A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid Raina, Deepak Bushan Matuszewski, Lucas-Maximilian Vater, Corina Bolte, Julia Isaksson, Hanna Lidgren, Lars Tägil, Magnus Zwingenberger, Stefan Sci Adv Research Articles Bone morphogenic proteins (BMPs) are the only true osteoinductive molecules. Despite being tremendously potent, their clinical use has been limited for reasons including supraphysiological doses, suboptimal delivery systems, and the pro-osteoclast effect of BMPs. Efforts to achieve spatially controlled bone formation using BMPs are being made. We demonstrate that a carrier consisting of a powder of calcium sulfate/hydroxyapatite (CaS/HA) mixed with bone active molecules provides an efficient drug delivery platform for critical femoral defect healing in rats. The bone-active molecules were composed of osteoinductive rhBMP-2 and the bisphosphonate, and zoledronic acid (ZA) was chosen to overcome BMP-2–induced bone resorption. It was demonstrated that delivery of rhBMP-2 was necessary for critical defect healing and restoration of mechanical properties, but codelivery of BMP-2 and ZA led to denser and stronger fracture calluses. Together, the CaS/HA biomaterial with rhBMP-2 and/or ZA can potentially be used as an off-the-shelf alternative to autograft bone. American Association for the Advancement of Science 2020-11-27 /pmc/articles/PMC7695465/ /pubmed/33246951 http://dx.doi.org/10.1126/sciadv.abc1779 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Research Articles Raina, Deepak Bushan Matuszewski, Lucas-Maximilian Vater, Corina Bolte, Julia Isaksson, Hanna Lidgren, Lars Tägil, Magnus Zwingenberger, Stefan A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title | A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title_full | A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title_fullStr | A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title_full_unstemmed | A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title_short | A facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
title_sort | facile one-stage treatment of critical bone defects using a calcium sulfate/hydroxyapatite biomaterial providing spatiotemporal delivery of bone morphogenic protein–2 and zoledronic acid |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695465/ https://www.ncbi.nlm.nih.gov/pubmed/33246951 http://dx.doi.org/10.1126/sciadv.abc1779 |
work_keys_str_mv | AT rainadeepakbushan afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT matuszewskilucasmaximilian afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT vatercorina afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT boltejulia afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT isakssonhanna afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT lidgrenlars afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT tagilmagnus afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT zwingenbergerstefan afacileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT rainadeepakbushan facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT matuszewskilucasmaximilian facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT vatercorina facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT boltejulia facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT isakssonhanna facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT lidgrenlars facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT tagilmagnus facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid AT zwingenbergerstefan facileonestagetreatmentofcriticalbonedefectsusingacalciumsulfatehydroxyapatitebiomaterialprovidingspatiotemporaldeliveryofbonemorphogenicprotein2andzoledronicacid |